Federal health authorities have alerted the public to serious safety risks from compounded injections containing the peptide glutathione, following reports of dozens of people becoming ill — with several requiring hospital care.
The U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are investigating a cluster of illnesses linked to injectable products containing glutathione, a substance widely marketed for energy boosts, anti-aging benefits, and liver detoxification. As of September 23, 2026, dozens of adverse events have been reported, with some patients experiencing severe reactions that led to hospital admission. The FDA has issued a public advisory urging consumers to exercise extreme caution and to discontinue use of these products immediately.
Glutathione is a naturally occurring antioxidant produced in the human body. In recent years, compounded formulations — often prepared outside standard pharmaceutical manufacturing channels — have grown in popularity in wellness clinics, medi-spas, and alternative health centres. Proponents claim intravenous or injected delivery provides superior absorption and transformative health effects, but these purported benefits have not been validated through rigorous clinical trials, and the FDA has not approved glutathione injections for cosmetic or general wellness use.
Investigators have not yet pinpointed the exact cause of the illnesses, but suspect contamination, inconsistent dosing, or improper preparation in the compounding process. Many of the affected individuals received treatments at independent facilities, and the products involved do not carry FDA approval labels. Health officials emphasise that when substances are administered by injection, any contamination or quality defect poses far greater risk than oral use, potentially leading to serious infection, organ damage, or life-threatening reactions.
Authorities advise anyone who has received glutathione injections and experienced symptoms such as fever, chills, nausea, dizziness, or unusual pain or swelling to seek medical attention promptly and report the incident to their healthcare provider. The FDA also encourages providers and patients to report adverse events directly through the agency's MedWatch safety reporting system. Investigations are ongoing to identify the specific batches or suppliers involved and to determine whether additional cases remain unreported.
Post a Comment